摘要
目的 探讨子宫颈癌血清与组织尿激酶型纤溶酶原激活物受体（uPAR）与患者病理特征的关系及其临床意义。方法免疫组织化学染色（SABC法）检测50例子宫颈癌组织与正常子宫组织uPAR表达；酶联免疫吸附测定（ELISA）法检测68例子宫颈癌组织及血清uPAR水平。结果50例子宫颈癌组织中33例uPAR表达，阳性表达率66％，正常组织无表达。子宫颈癌组织uPARf（70．924-28．55）ng／100mg蛋白]、血清uPAR[（2．38±0．29）ng／ml]高于癌旁组织[（11．01±5．40）ng／100mg蛋白]、对照组[（0．504±0．16）ng／m1]（均P〈0．001）；组织uPAR水平与患者临床分级、淋巴结转移及分化程度相关，而与肿瘤浸润、癌栓形成无关。术前子宫颈癌患者血清uPAR水平与临床分级、淋巴结转移、癌栓、浸润深度有关（P〈0．05～P〈0．01）；与分化程度无关。多元逐步回归分析提示，影响术前血清uPAR的因素是临床分期、盆腔淋巴结转移、肌层侵犯深度（均P=0．001）。与术前比较，术后子宫颈癌患者血清uPAR水平下降，差异有统计学意义（P〈0．001）。血清与组织uPAR含量呈正相关（r=0．801，P〈0．001）。结论uPAR在子宫颈癌组织及血清中高表达，血清uPAR与患者临床分级、盆腔淋巴结转移及肿瘤浸润有关，可作为子宫颈癌诊断、病情检测及预后评判的一项标志物。
Objective To analyze the correlation between the levels of urinary ptasminogen activator receptor （uPAR） and the clinieopathologieal characteristics of patients with cervical carcinoma and it＂ s clinical significance. Methods SABC immnnobistocbemistry was employed to detect the expression of uPAR in 50 cases of cervical carcinoma tissue and 50 cases of normal cervical tissue. ELISA method was used to determine the serum uPAR levels for the patients with cervical carcinoma. Results There was no expression for uPAR in normal tissues, The positive expression rate of uPAR was 66 % （33/50）. The uPAR level of cervix cancer tissues [（70.92±28.55） ng/100 nag protein） was significantly higher than those in normal tissues [（11.01±5.40） ng/100 mg protein], （P 〈0.00l）. and uPAR levels were closely related to clinical stages, lymphatic metastasis and differentiation degree （P 〈0.05）, but not related to deep myometrial invasion and vascular embolization （P 〉0,05） （however, they were not related to patient＇s age, tumor growth type and the size of tumor, Significant difference of uPAR level was observed between the patients with cervical carcinoma [（2.38±0.29） ng/ml] and in healthy controls [（0.50±0.16） ng/ml] （P 〈0.001）. Single factor analysis indicated that, before the treatment, the serum uPAR levels were closely related to clinical stages, lymphatic metastasis, vascular embolization, and deep myometrial invasion （P 〈0.05-P 〈0.01）. However, they were not related to differentiation degree （P 〉0.05）. Muhifactor regression analysis showed that the pretreatment serum uPAR levels of patients were related to clinical stages （P =0.000）, cavum pelvis lymphatic metastasis （P =0.000） and deep myometrial invasion. Patients with cervical carcinoma showed a dramatic drop in serum uPAR levels after treatment, which were significantly different compared to their pretreatment uPAR levels （P 〈0.001）. Linear correlation analysis showed that there was a positive correlation between serum and tissue uPAR levels, （r =0.801, P 〈0.001）. Conclusion There were high expression of uPAR in serum and tissues with cervical carcinoma. Pretreatment serum uPAR levels were closely related to patients＂ clinical stages, cavum pelvis lymphatic metastasis and deep myometrial invasion, serum uPAR levels may be an important tumor marker for the diagnosis, detection, prognosis of cervical caroinoma.
出处
《肿瘤研究与临床》
CAS
2011年第3期164-167,共4页
Cancer Research and Clinic
基金
山西省卫生厅科技基金（200743）
关键词
子宫颈肿瘤
血清
组织
尿纤溶酶原激活物
Uterina cervical neoplasms
Serum
Tissues
Urinary ptasminogen activator
作者简介
通信作者：荆结线，Email：byshcz@vip．163．com
